chloroquine has been researched along with Infections, Respiratory in 9 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chloroquine-azithromycin is being evaluated as combination therapy for malaria." | 9.19 | Chloroquine-azithromycin combination antimalarial treatment decreases risk of respiratory- and gastrointestinal-tract infections in Malawian children. ( Claassen, CW; Dzinjalamala, FK; Gilliams, EA; Jumare, J; Laufer, MK; Nyirenda, OM; Plowe, CV; Taylor, T; Thesing, PC; Tracy, LA, 2014) |
| "Chloroquine-azithromycin is being evaluated as combination therapy for malaria." | 5.19 | Chloroquine-azithromycin combination antimalarial treatment decreases risk of respiratory- and gastrointestinal-tract infections in Malawian children. ( Claassen, CW; Dzinjalamala, FK; Gilliams, EA; Jumare, J; Laufer, MK; Nyirenda, OM; Plowe, CV; Taylor, T; Thesing, PC; Tracy, LA, 2014) |
| " A physiologically based pharmacokinetic model with detailed respiratory physiology was used to predict regional airway exposure and optimize dosing regimens." | 1.72 | Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections. ( Calvino-Martin, F; Hoeng, J; Kolli, AR, 2022) |
| " Therefore, rOC43-ns2DelRluc represents a promising safe and sensitive platform for high-throughput antiviral screening and quantitative analysis of viral replication." | 1.43 | Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene. ( Desforges, M; Liu, G; Shen, L; Talbot, PJ; Tan, W; Yang, Y; Ye, F, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Kolli, AR | 1 |
| Calvino-Martin, F | 1 |
| Hoeng, J | 1 |
| Holtz, LR | 1 |
| Tarr, PI | 1 |
| Gilliams, EA | 1 |
| Jumare, J | 1 |
| Claassen, CW | 1 |
| Thesing, PC | 1 |
| Nyirenda, OM | 1 |
| Dzinjalamala, FK | 1 |
| Taylor, T | 1 |
| Plowe, CV | 1 |
| Tracy, LA | 1 |
| Laufer, MK | 1 |
| Rongey, C | 1 |
| Cherian, S | 1 |
| Shen, L | 1 |
| Yang, Y | 1 |
| Ye, F | 1 |
| Liu, G | 1 |
| Desforges, M | 1 |
| Talbot, PJ | 1 |
| Tan, W | 1 |
| Keyaerts, E | 1 |
| Li, S | 1 |
| Vijgen, L | 1 |
| Rysman, E | 1 |
| Verbeeck, J | 1 |
| Van Ranst, M | 1 |
| Maes, P | 1 |
| WARLEY, MA | 1 |
| HAMILTON, PJ | 1 |
| MARSDEN, PD | 1 |
| BROWN, RE | 1 |
| MERSELIS, JG | 1 |
| WILKS, N | 1 |
| Nahum, A | 1 |
| Erhart, A | 1 |
| Gazard, D | 1 |
| Agbowai, C | 1 |
| Van Overmeir, C | 1 |
| van Loen, H | 1 |
| Menten, J | 1 |
| Akogbeto, M | 1 |
| Coosemans, M | 1 |
| Massougbodji, A | 1 |
| D'Alessandro, U | 1 |
| Baker, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19[NCT04353037] | Phase 2 | 39 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 1-3 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 4 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 15-17 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 6 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Co-inhabitants of COVID-19 positive PCR patients in self-quarantine that test positive up to 31 days after patient begins treatment with HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month period (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Number of COVID-19+ PCR patients in self-quarantine who are hospitalized up to 31 days after beginning HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQ (NCT04353037)
Timeframe: Until completion of study, 2 months (~60 days) after start of treatment.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| moderate adverse events | minor adverse events | |
| Sub Study 2 Group 1 (HCQ) | 2 | 1 |
| Sub Study 2 Group 2 (Placebo) | 0 | 0 |
1 review available for chloroquine and Infections, Respiratory
| Article | Year |
|---|---|
Psoriasis--clinical features.
Topics: Acrodermatitis; Arthritis, Infectious; Arthritis, Reactive; Child; Child, Preschool; Chloroquine; Di | 1971 |
2 trials available for chloroquine and Infections, Respiratory
| Article | Year |
|---|---|
Chloroquine-azithromycin combination antimalarial treatment decreases risk of respiratory- and gastrointestinal-tract infections in Malawian children.
Topics: Antimalarials; Azithromycin; Child, Preschool; Chloroquine; Drug Therapy, Combination; Female; Gastr | 2014 |
Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa.
Topics: Analysis of Variance; Anemia; Animals; Antimalarials; Artemisinins; Artesunate; Benin; Child, Presch | 2007 |
6 other studies available for chloroquine and Infections, Respiratory
| Article | Year |
|---|---|
Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.
Topics: Administration, Inhalation; Aerosols; Algorithms; Cell Line; Chloroquine; COVID-19; Cytosol; Humans; | 2022 |
Unexplained benefits of antibiotics in childhood: empiricism in need of enlightenment.
Topics: Antimalarials; Azithromycin; Chloroquine; Female; Gastrointestinal Diseases; Humans; Malaria; Male; | 2014 |
Effects of chloroquine therapy on white blood cells.
Topics: Adult; Anti-Infective Agents; Chloroquine; Female; Humans; Leukocyte Count; Leukocytes; Lupus Erythe | 2015 |
Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene.
Topics: Antiviral Agents; Cell Line; Chloroquine; Coronavirus Infections; Coronavirus OC43, Human; Genes, Re | 2016 |
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
Topics: Animals; Animals, Newborn; Antiviral Agents; Cell Line, Tumor; Cell Survival; Chloroquine; Coronavir | 2009 |
CHEMOPROPHYLAXIS OF HOMOZYGOUS SICKLERS WITH ANTIMALARIALS AND LONG-ACTING PENICILLIN.
Topics: Adolescent; Anemia; Anemia, Sickle Cell; Antimalarials; Biomedical Research; Chemoprevention; Child; | 1965 |